AUTOIMMUNE DISEASE;
B LYMPHOCYTE;
COMPLEMENT INHIBITION;
DRUG COST;
DRUG MANUFACTURE;
EDITORIAL;
GLOMERULOPATHY;
HUMAN;
KIDNEY TRANSPLANTATION;
NONHUMAN;
ORGAN TRANSPLANTATION;
PRIORITY JOURNAL;
T LYMPHOCYTE;
TREATMENT DURATION;
Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation
Kroshus TJ, Rollins SA, Dalmasso AP, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-human xenotransplantation. Transplantation 1995; 60: 1194-1202. (Pubitemid 26005270)
Inhibition of terminal complement components in presensitized transplant models prevents antibody mediated rejection leading to long-term graft survival and accommodation
Wang H, Arp J, Liu W, et al. Inhibition of terminal complement components in presensitized transplant models prevents antibody mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007; 179: 4451-4463.
The use of antibody to complement protein C5 for salvage treatment of severe antibodymediated rejection
Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibodymediated rejection. Am J Transplant 2009; 9: 231-235.
C4d and C3d staining in biopsies of ABO- and HLA-Incompatible renal allografts: Correlation with histologic findings
DOI 10.1111/j.1600-6143.2006.01356.x
Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6: 1829-1840. (Pubitemid 44024954)
